Healthy
Conditions
Brief summary
Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit the bone resorption. However, the mechanism is unknown. In the present study we will investigate the mechanism of action using a receptor specific inhibitor.
Interventions
OTHERInhibitor + GLP-2
Inhibitor and GLP-2 are used as study tools.
OTHERPlacebo + GLP-2
Placebo and GLP-2 are used as study tools.
OTHERPlacebo + GIP
Placebo and GIP are used as study tools.
OTHERPlacebo + Saline
Placebo
Sponsors
Hvidovre University Hospital
University of Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy, 20 to 40 years old, caucasian, BMI 18,5 to 24,9 kg/m2
Exclusion criteria
* Chronic disease, smoking, medication, weight change more than 3 kg whitin the last 3 months, overweight surgery, intestinal surgery, Hgb\<8,0 mmol/L, decreased renal function.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| C-terminal telopeptide (CTX) | -30 to 240 min. | Marker of bone resorption |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Osteocalcin (OC) | -30 to 240 min. | Bone marker |
| Parathyroid hormone (PTH) | -30 to 240 min. | Bone marker |
| Osteoprotegerin (OPG) | -30 to 240 min. | Bone marker |
| Glucose-dependent insulinotropic polypeptide (GIP) | -30 to 240 min. | GIP total and intact |
| N-terminal propeptide of type 1 procollagen (P1NP) | -30 to 240 min. | Marker of bone formation |
| Glukagon and pancreatic polypeptide (PP) | -30 to 240 min. | — |
| Glucose | -30 to 240 min. | — |
| Insulin/c-pep. | -30 to 240 min. | — |
| Glukagon-like peptide-1 (GLP-1) and glukagon-like peptide-2 (GLP-2) | -30 to 240 min. | — |
Countries
Denmark
Outcome results
None listed